Terlipressin acetate is a Vasotocin analogue with potent vasoactive properties. Terlipressin acetate is a highly selective Vasotocin V1 receptor agonist that reduces the splanchnic blood flow and portal pressure and controls acute variceal bleeding. Terlipressin acetate exerts anti-inflammatory and anti-oxidative effects. Terlipressin acetate has the potential for hepatorenal syndrome and norepinephrine-resistant septic shock researchIn VitroTerlipressin (25 nM; 24-72 hours; IEC-6 cells) treatment significantly improves cell viability, proliferation and apoptosis in IEC-6 cells. Terlipressin inhibits the secretion of TNF-α and 15-F2t-isoprostane from IEC-6 cells following oxygen and glucose deprivation/re-oxygenation (OGD/R). Terlipressin administration following OGD attenuates OGD/R-induced cell damage via the PI3K signaling pathway. MCE has not independently confirmed the accuracy of these methods. They are for reference only. Cell Proliferation AssayCell Line: IEC-6 cells induced by oxygen and glucose deprivation/re-oxygenation (OGD/R) Concentration: 25 nM Incubation Time: 24 hours, 48 hours, 72 hours Result: Significantly increased the proliferation of IEC-6 cells.In VivoUsing a mouse nonlethal hepatic ischemia-reperfusion (IR) model, Terlipressin administration significantly ameliorates IR-induced liver apoptosis, necrosis and inflammation. MCE has not independently confirmed the accuracy of these methods. They are for reference only.Form:SolidIC50& Target:Vasotocin V1 receptor. Specification: 0.99 Molecular Formula: C56H82N16O19S2 Molecular Weight: 1347.48 PubChem CID: 72941948 Isomeric SMILES: CC(=O)O.CC(=O)O.C1C[C@H](N(C1)C(=O)[C@@H]2CSSC[C@@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N2)CC(=O)N)CCC(=O)N)CC3=CC=CC=C3)CC4=CC=C(C=C4)O)NC(=O)CNC(=O)CNC(=O)CN)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N
- UPC:
- 51182106
- Condition:
- New
- Availability:
- 8-12 weeks
- Weight:
- 1.06 Ounces
- HazmatClass:
- No
- WeightUOM:
- LB
- MPN:
- T651556-50mg
- CAS:
- 1884420-36-3
- Product Size:
- 50mg
